Valuation: Personalis, Inc.

Market Cap 1.69B 1.51B 1.41B 1.28B 2.4B 161B 2.42B 16.88B 6.61B 83.57B 6.36B 6.22B 268B P/E 2026 *
-14.7x
P/E 2027 * -16.9x
Enterprise Value 1.52B 1.35B 1.26B 1.14B 2.15B 144B 2.17B 15.11B 5.92B 74.8B 5.69B 5.57B 240B EV / Sales 2026 *
18x
EV / Sales 2027 * 14.5x
Free-Float
73.86%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week-1.12%
Current month-2.64%
1 month-2.22%
3 months+5.39%
6 months+151.19%
Current year+99.12%
1 week 15.79
Extreme 15.79
16.24
1 month 15.68
Extreme 15.68
16.77
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
21.69
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
Chief Executive Officer 65 31/12/2022
President 55 13/03/2026
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 A Sell

Chief Financial Officer

-2,931 0.0028%
9/18/26 A Sell

Chairperson

-3,998 0.0038%
9/18/26 A Sell

Chief Executive Officer

-7,459 0.0071%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%-1.12%+92.59%+1,395.28% 1.69B
-0.22%+1.30%+11.61%+22.38% 112B
+0.47%+6.61%+12.19%+94.07% 99.75B
-0.53%-1.25%+127.17%+852.47% 57.03B
+2.17%-3.24%-11.87%+65.77% 26.99B
-0.93%+0.91%+26.09%+88.13% 25.44B
-0.60%+0.62%+13.37%+55.61% 25.44B
-0.69%+3.27%+40.48%+393.46% 21.49B
-2.91%-3.42%-20.18%-4.05% 21.15B
-2.67%-0.29%+12.03%+94.79% 19.42B
Average -0.56%+0.59%+30.35%+305.79% 41.04B
Weighted average by Cap. -0.28%+1.77%+27.50%+191.32%

Financials

2026 *2027 *
Net sales 84.34M 75.34M 70.23M 63.67M 120M 8.01B 121M 841M 329M 4.16B 317M 310M 13.36B 110M 98.44M 91.76M 83.19M 157M 10.46B 158M 1.1B 430M 5.44B 414M 405M 17.46B
Net income -114M -102M -94.77M -85.92M -162M -10.8B -163M -1.14B -444M -5.62B -427M -418M -18.03B -100M -89.61M -83.52M -75.72M -143M -9.52B -144M -1B -392M -4.95B -377M -368M -15.89B
Net Debt -178M -159M -148M -134M -252M -16.86B -254M -1.77B -693M -8.77B -667M -652M -28.13B -91.04M -81.33M -75.8M -68.72M -129M -8.64B -130M -908M -355M -4.49B -342M -334M -14.42B
Projected Income Statement - Annual - Personalis, Inc.
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
13/10/26 $15.85 +0.32% 3,817,337
12/10/26 $15.80 -1.25% 2,254,343
09/10/26 $16.00 -0.37% 1,835,904
08/10/26 $16.06 +0.37% 1,467,492
07/10/26 $16.00 -0.19% 3,818,003
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Personalis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
15.85USD
Average target price
15.17USD
Spread / Average Target
-4.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Personalis, Inc.
  1. Stock Market
  2. Stocks
  3. PSNL Stock